Molecular mechanism of action for reversible P2Y12 antagonists

被引:9
|
作者
Liu, Haibo [2 ]
Ge, Hu [1 ]
Peng, Yong [2 ]
Xiao, Peigen [2 ]
Xu, Jun [1 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Plant Dev, Beijing 100194, Peoples R China
关键词
P2Y(12) receptor; ADP; Antagonists; Platelets aggregation; SWISS-MODEL REPOSITORY; CLOPIDOGREL PLUS ASPIRIN; ANTIPLATELET THERAPY; RECEPTOR ANTAGONIST; COST-EFFECTIVENESS; P2; RECEPTORS; FREE-ENERGY; PROTEIN; PREVENTION; P2Y12;
D O I
10.1016/j.bpc.2011.03.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, reversible antagonists of the P2Y(12) receptor have been reported. However, the mechanisms of binding have not been elucidated. To this end, a number of homology models were built by means of three programs from four templates. A consensus model was derived from those initial models. The final model was created by refining the consensus model with molecular dynamics simulations. The agonist and antagonists of P2Y(12) have been docked in the final model. For the agonist, the Arg256, Lys280, and Phe252 are "hot" residues. For the antagonists, the Lys280 and Phe252 are "hot" residues that have hydrogen bonding contacts and pi-pi interactions, respectively. These results can explain the observations of mutation experiments and can guide the design of new inhibitors. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:74 / 81
页数:8
相关论文
共 50 条
  • [11] Features of reversible P2Y12 receptor antagonists based on piperazinyl-glutamate-pyridines
    Zhang, Zhen
    Wu, Guanzhong
    Wang, Chengqian
    Jin, Xiao
    Li, Dong
    Lin, Kejiang
    MEDICINAL CHEMISTRY RESEARCH, 2016, 25 (06) : 1204 - 1215
  • [12] Features of reversible P2Y12 receptor antagonists based on piperazinyl-glutamate-pyridines
    Zhen Zhang
    Guanzhong Wu
    Chengqian Wang
    Xiao Jin
    Dong Li
    Kejiang Lin
    Medicinal Chemistry Research, 2016, 25 : 1204 - 1215
  • [13] Delayed onset of novel P2Y12 receptor antagonists action post fibrinolysis
    Alexopoulos, Dimitrios
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 234 : 131 - 131
  • [14] Reply: Delayed onset of novel P2Y12 receptor antagonists action post fibrinolysis
    Guimaraes, Leonardo de F. C.
    Stone, Gregg W.
    Caixeta, Adriano
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 234 : 132 - 132
  • [15] Adenine triphosphate nucleotides are antagonists at the P2Y12 receptor
    Kauffenstein, G
    Hechler, B
    Cazenave, JP
    Gachet, C
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (11) : 1980 - 1988
  • [16] P2Y12 antagonists as antiplatelet agents - Recent developments
    Bhavaraju, Kamala
    Mayanglambam, Azad
    Rao, A. Koneti
    Kunapuli, Satya P.
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2010, 13 (04) : 497 - 506
  • [17] To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question
    Lowenstern, Angela
    Newby, L. Kristin
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (09):
  • [18] Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists
    Henrich, Andrea
    Claussen, Christian Hove
    Dingemanse, Jasper
    Krause, Andreas
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (07): : 735 - 747
  • [19] The Pharmacodynamics of Switching Between P2Y12 Receptor Antagonists
    Price, Matthew J.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (11) : 1099 - 1101
  • [20] P2Y12 Receptor Antagonists and Morphine: A Dangerous Liaison?
    Giannopoulos, Georgios
    Deftereos, Spyridon
    Kolokathis, Fotios
    Xanthopoulou, Ioanna
    Lekakis, John
    Alexopoulos, Dimitrios
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (09)